Eli Lilly and Co
LLY738.210USD
-50.990-6.46%
Fechamento 04/04, 16:00（ET）Cotações atrasadas em 15 min
699.48BValor de mercado
66.05P/L TTM
Informações de Eli Lilly and Co Empresa
Eli Lilly and Company is a medicine company. The Company discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; and Zepbound. Its oncology products include Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing efforts, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of α4β7 integrin (known as MORF-057) for inflammatory bowel disease (IBD).
Informações da empresa
Código da empresaLLY
Nome da EmpresaEli Lilly and Co
Data de listagemJul 09, 1970
Fundado em1901
CEOMr. David A. (Dave) Ricks
Funcionários47000
Tipo de TítulosOrdinary Share
Fim do ano fiscalJul 09
EndereçoLilly Corporate Ctr
CidadeINDIANAPOLIS
Bolsa de ValoresNYSE Consolidated
PaísUnited States of America
Código postal46285
Telefone13172762000
Sitehttps://www.lilly.com/
Código da empresaLLY
Data de listagemJul 09, 1970
Fundado em1901
Executivos da Empresa
Nome
Nome/Posição
Posição
Ações Detidas
Variação
Dr. Daniel M. Skovronsky, M.D., Ph.D.
Dr. Daniel M. Skovronsky, M.D., Ph.D.
Executive Vice President, Chief Scientific Officer and President - Lilly Research Laboratories and Lilly Immunology
Executive Vice President, Chief Scientific Officer and President - Lilly Research Laboratories and Lilly Immunology
212.28K
+12.97%
Ms. Anne E. White
Ms. Anne E. White
Executive Vice President, President - Lilly Neuroscience
Executive Vice President, President - Lilly Neuroscience
74.21K
+13.18%
Mr. J. Erik Fyrwald
Mr. J. Erik Fyrwald
Independent Director
Independent Director
72.69K
+0.02%
Mr. Patrik Jonsson
Mr. Patrik Jonsson
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
54.13K
+20.12%
Ms. Anat Hakim
Ms. Anat Hakim
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
43.54K
+175.92%
Mr. Edgardo Hernandez
Mr. Edgardo Hernandez
Executive Vice President, President - Manufacturing Operations
Executive Vice President, President - Manufacturing Operations
39.75K
+4.13%
Mr. Ilya Yuffa
Mr. Ilya Yuffa
Executive Vice President, President of Lilly International
Executive Vice President, President of Lilly International
28.76K
+45.24%
Dr. Katherine Baicker, Ph.D.
Dr. Katherine Baicker, Ph.D.
Independent Director
Independent Director
23.16K
+0.62%
Mr. Diogo Rau
Mr. Diogo Rau
Executive Vice President, Chief Information and Digital Officer
Executive Vice President, Chief Information and Digital Officer
19.72K
+77.63%
Mr. Lucas E. Montarce
Mr. Lucas E. Montarce
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
13.97K
+26.18%
Ver Mais
Nome
Nome/Posição
Posição
Ações Detidas
Variação
Dr. Daniel M. Skovronsky, M.D., Ph.D.
Dr. Daniel M. Skovronsky, M.D., Ph.D.
Executive Vice President, Chief Scientific Officer and President - Lilly Research Laboratories and Lilly Immunology
Executive Vice President, Chief Scientific Officer and President - Lilly Research Laboratories and Lilly Immunology
212.28K
+12.97%
Ms. Anne E. White
Ms. Anne E. White
Executive Vice President, President - Lilly Neuroscience
Executive Vice President, President - Lilly Neuroscience
74.21K
+13.18%
Mr. J. Erik Fyrwald
Mr. J. Erik Fyrwald
Independent Director
Independent Director
72.69K
+0.02%
Mr. Patrik Jonsson
Mr. Patrik Jonsson
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
54.13K
+20.12%
Ms. Anat Hakim
Ms. Anat Hakim
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
43.54K
+175.92%
Mr. Edgardo Hernandez
Mr. Edgardo Hernandez
Executive Vice President, President - Manufacturing Operations
Executive Vice President, President - Manufacturing Operations
39.75K
+4.13%
Detalhamento da Receita
Moeda: USDTempo de atualização: há 4 horas
Moeda: USDTempo de atualização: há 4 horas
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Por EmpresaUSD
Nome
Receita
Proporção
Diabetes-Mounjaro
11.54B
25.62%
Oncology-Verzenio
5.31B
11.78%
Diabetes-Trulicity
5.25B
11.66%
Diabetes-Zepbound
4.93B
10.94%
Diabetes-Jardiance
3.34B
7.42%
Other
14.68B
32.58%
Por RegiãoUSD
Nome
Receita
Proporção
U.S.
30.38B
67.44%
Europe
6.92B
15.36%
Other foreign countries
4.27B
9.48%
Japan
1.81B
4.03%
China
1.66B
3.69%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Diabetes-Mounjaro
11.54B
25.62%
Oncology-Verzenio
5.31B
11.78%
Diabetes-Trulicity
5.25B
11.66%
Diabetes-Zepbound
4.93B
10.94%
Diabetes-Jardiance
3.34B
7.42%
Other
14.68B
32.58%
Acionista
Tempo de atualização: sex, 21 de fev
Tempo de atualização: sex, 21 de fev
Estatísticas do Acionista
Tipo
Estatísticas do Acionista
Acionista
Proporção
Lilly Endowment, Inc.
10.13%
The Vanguard Group, Inc.
7.80%
PNC Investments LLC
5.39%
BlackRock Institutional Trust Company, N.A.
4.34%
State Street Global Advisors (US)
3.62%
Other
68.73%
Estatísticas do Acionista
Acionista
Proporção
Lilly Endowment, Inc.
10.13%
The Vanguard Group, Inc.
7.80%
PNC Investments LLC
5.39%
BlackRock Institutional Trust Company, N.A.
4.34%
State Street Global Advisors (US)
3.62%
Other
68.73%
Tipo
Acionista
Proporção
Investment Advisor
37.91%
Investment Advisor/Hedge Fund
25.90%
Foundation
10.22%
Research Firm
1.93%
Pension Fund
1.88%
Bank and Trust
1.79%
Insurance Company
1.43%
Sovereign Wealth Fund
1.24%
Hedge Fund
1.10%
Other
16.61%
Instituição Participações
Tempo de atualização: qui, 20 de fev
Tempo de atualização: qui, 20 de fev
Período do Relatório
Nº de instituições
Ações detidas
Proporção
Variação
2025Q1
5515
795.05M
83.86%
+1.55M
2024Q4
5528
795.43M
83.87%
+627.51K
2024Q3
5177
793.57M
83.49%
-5.03M
2024Q2
5068
795.80M
83.72%
-2.01M
2024Q1
4916
795.04M
83.62%
-6.22M
2023Q4
4670
799.46M
84.21%
-2.37M
2023Q3
4354
800.21M
84.30%
-1.19M
2023Q2
4197
799.48M
84.22%
-4.32M
2023Q1
4061
801.36M
84.15%
-9.39M
2022Q4
3985
805.64M
84.79%
-7.51M
Ver Mais
Atividade dos Acionistas
Nome
Ações detidas
Proporção
Variação
Chg %
Data
Lilly Endowment, Inc.
96.02M
10.13%
-220.00K
-0.23%
Mar 03, 2025
The Vanguard Group, Inc.
73.90M
7.8%
+486.78K
+0.66%
Dec 31, 2024
PNC Investments LLC
51.08M
5.39%
-49.68K
-0.10%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
41.11M
4.34%
+29.75K
+0.07%
Dec 31, 2024
State Street Global Advisors (US)
34.31M
3.62%
+461.69K
+1.36%
Dec 31, 2024
Fidelity Management & Research Company LLC
29.35M
3.1%
-2.42M
-7.60%
Dec 31, 2024
T. Rowe Price Associates, Inc.
19.73M
2.08%
-77.25K
-0.39%
Dec 31, 2024
Capital World Investors
19.55M
2.06%
-803.44K
-3.95%
Dec 31, 2024
Geode Capital Management, L.L.C.
17.38M
1.83%
+291.88K
+1.71%
Dec 31, 2024
PRIMECAP Management Company
16.76M
1.77%
-933.85K
-5.28%
Dec 31, 2024
Ver Mais
ETFs Relacionados
Tempo de atualização: há 16 horas
Tempo de atualização: há 16 horas
Nome
Proporção
Defiance Daily Target 2X Long LLY ETF
30.83%
iShares U.S. Pharmaceuticals ETF
21.6%
Amplify Weight Loss Drug & Treatment ETF
18.44%
Roundhill GLP-1 & Weight Loss ETF
18.11%
VanEck Pharmaceutical ETF
12.4%
Proshares Ultra Health Care
12.21%
Health Care Select Sector SPDR Fund
11.98%
iShares U.S. Healthcare ETF
11.95%
Fidelity MSCI Health Care Index ETF
11.93%
Simplify Health Care ETF
11.07%
Ver Mais
Defiance Daily Target 2X Long LLY ETF
Proporção30.83%
iShares U.S. Pharmaceuticals ETF
Proporção21.6%
Amplify Weight Loss Drug & Treatment ETF
Proporção18.44%
Roundhill GLP-1 & Weight Loss ETF
Proporção18.11%
VanEck Pharmaceutical ETF
Proporção12.4%
Proshares Ultra Health Care
Proporção12.21%
Health Care Select Sector SPDR Fund
Proporção11.98%
iShares U.S. Healthcare ETF
Proporção11.95%
Fidelity MSCI Health Care Index ETF
Proporção11.93%
Simplify Health Care ETF
Proporção11.07%
Dividendo
Um total de
18.06B
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro das ações
Data de pagamento
Data de ex-dividendo
Dec 09, 2024
LLY.NB Interim Cash Dividend of gross USD 1.5 paid on Mar 10, 2025 going ex on Feb 14, 2025
Feb 14, 2025
Mar 10, 2025
Feb 14, 2025
Oct 28, 2024
LLY.NB Final Cash Dividend of gross USD 1.3 paid on Dec 10, 2024 going ex on Nov 15, 2024
Nov 15, 2024
Dec 10, 2024
Nov 15, 2024
Jun 24, 2024
LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Sep 10, 2024 going ex on Aug 15, 2024
Aug 15, 2024
Sep 10, 2024
Aug 15, 2024
May 06, 2024
LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Jun 10, 2024 going ex on May 15, 2024
May 16, 2024
Jun 10, 2024
May 15, 2024
Dec 08, 2023
LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Mar 08, 2024 going ex on Feb 14, 2024
Feb 15, 2024
Mar 08, 2024
Feb 14, 2024
Nov 01, 2023
LLY.NB Final Cash Dividend of gross USD 1.13 paid on Dec 08, 2023 going ex on Nov 14, 2023
Nov 15, 2023
Dec 08, 2023
Nov 14, 2023
Jun 26, 2023
LLY.NB Interim Cash Dividend of gross USD 1.13 paid on Sep 08, 2023 going ex on Aug 14, 2023
Aug 15, 2023
Sep 08, 2023
Aug 14, 2023
May 01, 2023
LLY.NB Interim Cash Dividend of gross USD 1.13 paid on Jun 09, 2023 going ex on May 12, 2023
May 15, 2023
Jun 09, 2023
May 12, 2023
Dec 12, 2022
LLY.NB Interim Cash Dividend of gross USD 1.13 paid on Mar 10, 2023 going ex on Feb 14, 2023
Feb 15, 2023
Mar 10, 2023
Feb 14, 2023
Oct 17, 2022
LLY.NB Final Cash Dividend of gross USD 0.98 paid on Dec 09, 2022 going ex on Nov 14, 2022
Nov 15, 2022
Dec 09, 2022
Nov 14, 2022
Ver Mais
Desdobramento de Ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados